WELCOME
This website has been prepared by members of AngioGenex, Inc., a public company that trades on NSADAQ, OTC (AGGX.OB). Our goal is to describe the proprietary INHIBITOR OF DIFFERENTIATION (Id) technology of the Company and the business opportunity that it presents. As you review this information it will be apparent why a small group of professionals continue to be committed to this technology after ten years. Simply stated, members of the Company are convinced that our technology offers an unprecedented opportunity to develop drugs that are highly effective and safe in the treatment of cancer. To us, nothing would be more rewarding than bringing new and unique anti-cancer drugs into clinical use. Unlike many other companies, our scientists work closely with the source of the new information on which our efforts are based, and contribute to the advancement of the science. As with many other smaller companies, there have been significant difficulties in obtaining funds to maintain the Company and to conduct research and development in this highly promising scientific area. As a result, all funds have been used to maintain the company and to advance the research. Despite these problems, the science has continued to advance and to demonstrate the importance and potential of this technology, further confirming our commitment to its development. As you review the information in our website, we believe that you will conclude that AngioGenex, Inc. has the potential to bring new and more effective anti-cancer drugs to the market offering an unusual opportunity for the investor to support a promising approach to “the war on cancer” and to gain significant returns on their investment.
